Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS)
Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS)
The aim of the present positive-control study is to analyze and compare the rate of off-table
 subclinical neurological events in two groups of patients submitted to carotid artery
 stenting (CAS) with two different kind of stents, a close-cell stent, and the new
 mesh-covered stent, so to verify if the new model of stent is effective in preventing
 postprocedural carotid plaque embolism.
Scientific background and explanation of rationale: CAS in selected asymptomatic patients has
 proven to be effective in reducing the risk of carotid-related neurological ischemic events
 in selected patients. It also carries a not-negligible risk of intraprocedural and
 postprocedural (so-called "off-table") embolic events causing clinical (TIA, stroke, death)
 and subclinical (Magnetic Resonance Imaging - MRI-detectable microembolic brain lesions,
 cognitive impairment, increase in markers of brain injury) morbidity. CAS technique has
 progressively refined in order to minimize the risk of intraprocedural embolism, but despite
 the increasing use of close-cell design stents the risk of plaque prolapse through the stent
 struts and of postprocedural embolism still exists. In order to prevent plaque prolapse a new
 stent design has been conceived and realized. It combines the traditional open-cell design to
 an exterior PET mesh that is able to capture and keep in place plaque debris as small as
 150-180µm.

 The aim of the present positive-control study is to analyze and compare the rate of off-table
 subclinical neurological events in two groups of patients submitted to CAS with two different
 kind of stents, a close-cell stent, and the new mesh-covered stent, so to verify if the new
 model of stent is effective in preventing postprocedural carotid plaque embolism.

 Methods

 Trial Design: single-center, superiority, randomized controlled trial comparing results
 between two different carotid stents in patients affected by asymptomatic ≥70% carotid artery
 stenosis.

 Participants:

 CAS inclusion criteria are: age more than 55 years, presence of a carotid stenosis ≥70%
 (NASCET evaluation criteria), with no previous neurologic symptoms referred in the medical
 history, absence of a previous brain ischemic lesion detected at Diffusion Weighted (DW)-MRI.
 Patients with symptomatic carotid lesions, previous ischemic lesions detected at DW-MRI, or
 inability to give consent will be excluded from the study.

 Exclusion criteria for CAS are: significant contraindications to angiography, history of
 bleeding disorder, or intracranial aneurysm or vascular malformation or hemorrhage, presence
 of intraluminal thrombus, poor entry points at the femoral artery, type 2-3 arch, bovine
 arch, severe aortic arch or ipsilateral ostial common carotid or brachiocephalic
 atherosclerosis, severe proximal common or distal internal carotid artery tortuosity, sharply
 angulated internal carotid artery, carotid string sign, circumferential calcification of
 carotid plaque, length of the target lesion requiring more than one stent.

 Eligibility criteria for randomization are: obtained informed consent, compliance to the
 study protocol. Patients will be randomized to receive either carotid Wallstent (Boston
 Scientific, Marlborough, MA, USA) or C-Guard carotid stent (Inspire-MD, Tel-Aviv, Israel) a
 new mesh-covered open-cell stent.

 Written informed consent will be obtained before enrollment. Setting: data will be collected
 and analyzed at our Vascular Unit Academic Centre.

 Interventions: CAS interventions will be performed with distal embolic protection device in
 all cases (Filterwire, Boston Scientific, Marlborough, MA, USA) . Wallstent or C-Guard stent
 will be alternatively used to cover the whole plaque surface.

 DW-MRI performance: all patients will be submitted to preoperative, immediate postoperative,
 and 72 hours postoperatively DW-MRI. The comparison between immediate postoperative and
 72-hour examinations will detect any off-table events. Presence of recent ischemic lesions at
 preoperative examination will be considered an exclusion criterion for entering the study.

 MiniMentalStateExamination (MMSE) Test and MontrealCognitive Assessment (MOCA) Test
 administration and interpretation: all patients will be submitted to preoperative and 72-hour
 postoperative MMSE and MOCA tests in order to prove the effect of CAS-related microemboli on
 cognitive performance. The research assistant responsible for performing the tests
 preoperatively and postoperatively in all patients is trained to administer and score the
 tests. Downgrading in the postoperative examination, such as from normal to some cognitive
 impairment (1 step) or a difference ≥4 in the postoperative score compared with the
 preoperative value will be considered significant. No psychotropic or sedative medications
 will be administered to the patients before performing tests.

 NeuroSpecificEnolase (NSE) and S100β serum levels detection and analysis: The S100 test
 measures the β-subunit of protein S100 as defined by three monoclonal antibodies with a
 detection limit of 0.02 µg/L. NSE measurement is based on monoclonal antibodies that bind to
 the γ-subunit of the enzyme with a minimal measurable concentration of 0.3 µg/L. S100β and
 NSE proteins will be analyzed by the use of automated immunoluminometric assays (S100 Elecsys
 test, Roche Diagnostics GmbH, Mannheim, Germany; ELSA-NSE, CIS Bio International,
 Gif-sur-Yvette Cedex, France). Venous blood samples will be obtained for each patient
 preoperatively (basal sample), at 5 minutes after embolic protection device retrieval, and at
 2, 12, 24, and 48 hours after the end of the procedure. Samples will be allowed to clot.
 After centrifugation (1800g for 6 minutes) ≤20 minutes from collection, serum will be stored
 at -80°C for later analysis.

 Objective: to demonstrate a decrease in off-table microembolic event rate in patients
 submitted to CAS with C-Guard stent implantation compared to patients with Wallstent
 implantation, detected by DW-MRI, markers of brain injury, and neuropsychometric tests.

 Sample size estimation: assuming a type I error α=0.05, a type II error β=0.20, so a power
 (1-β)=0.80, an event rate in the control (Wallstent) group of 0.40 (40%), an event rate in
 the treatment (C-Guard) group of 0.10 (10%), so assuming a 30% event rate reduction in the
 treatment group, the estimation of sample size for each treatment group is 29.

 Randomisation: a computer-generated random allocation sequence would be used. A blocked
 randomization will be performed with an allocation ratio 1:1. Allocation concealment will be
 used. Blind postprocedural DW-MRI assessment/interpretation, neurobiomarkers levels
 evaluation, and MMSE and MOCA administration will be done by those assessing outcomes.
Inclusion Criteria:

 -  presence of a carotid stenosis ≥70% (NASCET evaluation criteria)

 -  no previous neurologic symptoms referred in the medical history

 -  absence of a previous brain ischemic lesion detected at DW-MRI

 Exclusion Criteria:

 -  symptomatic carotid lesions

 -  previous ischemic brain lesions detected at DW-MRI

 -  inability to give consent

 Exclusion criteria for CAS are:

 -  significant contraindications to angiography,

 -  history of bleeding disorder,

 -  intracranial aneurysm or vascular malformation or hemorrhage,

 -  presence of intraluminal thrombus,

 -  poor entry points at the femoral artery,

 -  type 2-3 arch,

 -  bovine arch,

 -  severe aortic arch or ipsilateral ostial common carotid or brachiocephalic
 atherosclerosis,

 -  severe proximal common or distal internal carotid artery tortuosity,

 -  sharply angulated internal carotid artery,

 -  carotid string sign,

 -  circumferential calcification of carotid plaque,

 -  length of the target lesion requiring more than one stent